HIF1A and breast cancer: Our exploratory analyses suggested that breast cancer patients in the ER−/TAM− group who had positive HIF-1α expression in their primary and recurrent tumors were more likely to have had early recurrence (< 5 years), although the small sample size yielded imprecise results.